Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings
Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). It is also used as an appropriate treatment of chronic myelomonocytic leukemia (CMML) in the real life setting. As treat...
Main Authors: | Nikolova D., Yordanov A., Radinov A. |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2021-10-01
|
Series: | Acta Medica Bulgarica |
Subjects: | |
Online Access: | https://doi.org/10.2478/amb-2021-0030 |
Similar Items
-
An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
by: Anwarul Islam
Published: (2023-08-01) -
Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia
by: Luka Čemažar, et al.
Published: (2020-12-01) -
A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
by: Asude Kara, et al.
Published: (2017-05-01) -
Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes
by: Moreno Vanegas Y, et al.
Published: (2022-12-01) -
Bridging-to-transplant with azacitidine for myelodysplastic syndrome and acute myeloid leukemia, reduces the incidence of acute graft-versus-host disease
by: Koichi Murakami, et al.
Published: (2017-06-01)